



Office de la propriété  
intellectuelle  
du Canada

organisme  
Industrie Canada

Canadian  
Intellectual Property  
Office

An Agency of  
Industry Canada

(11) © 1,341,211  
(21) 603,638  
(22) 1989/06/22  
(45) 2001/03/27  
(52) 195-1.235  
C.L. CR 167-103.41  
195-1.22  
195-1.32  
195-1.35  
530-7.40

(51) Int.Cl. <sup>7</sup> C12N 15/17; C07K 14/62; C12N 5/10; C12N 15/62; C07K 19/00

(19) (CA) **CANADIAN PATENT** (12)

(54) Mini-Proinsulin, Its Preparation and Use

(72) Dörschug, Michael, Germany  
Habermann, Paul, Germany  
Seipke, Gerhard, Germany  
Uhlmann, Eugen, Germany

(73) HOECHST AKTIENGESELLSCHAFT, Germany

(30) (DE) Germany P 38 21 159.9 1988/06/23

(57) 19 Claims

Canada

<http://opic.gc.ca> • Ottawa-Hull K1A 0C9 • <http://cipo.gc.ca>  
OPIC-CIPO 191

OPIC  CIPO

BEST AVAILABLE COPY

1341211

603,638

MAR 27 2001

Abstract of the disclosure:

**Mini-proinsulin, its preparation and use**

A mini-proinsulin, in which the amino acid Arg bridges the A and the B chain instead of the C chain, shows insulin activity and is suitable for the preparation of pharmaceuticals for the treatment of diabetes mellitus. It can furthermore be converted into an insulin derivative simply using trypsin, the B chain of which is lengthened by Arg. This can be converted into insulin using carboxypeptidase B. Advantageously, however, the mini-proinsulin can also be converted to insulin directly in a one-pot process.

## Description

## Mini-proinsulin, its preparation and use

5 The invention relates to a novel "mini-proinsulin" in which the unshortened B chain is only bonded to the A chain via an arginine residue. Human insulin is accessible from this mini-proinsulin without difficult chemical reaction.

10 Mini-proinsulins having a shortened C chain are known. Thus R. Wetzel et al., Gene 16 (1981), 63-71 have described a proinsulin having a C chain shortened to six amino acids. In the European patent application having the publication number (EP-A) 0,055,945 (Published 14 July 1982), corresponding proinsulins are disclosed, the C chain  
15 of which is shortened by two amino acids.

In EP-A 0,163,529 (Published 04 December 1985), insulin precursors having a shortened B chain are disclosed in which the C chain is either missing completely or else shortened to one amino acid. These precursors are converted into mature  
20 human insulin by trypsin-catalysed transpeptidation using an  $\alpha$ -threonine ester.

On the other hand, the invention relates to human Des-(32-65) proinsulin or mini-proinsulin of the formula I




25 in which B(1-30) and A(1-21) denote the B and A chain of human insulin. This compound is used not only as an intermediate for the preparation of human insulin Arg<sup>B31</sup>-OH, called "mono-Arg-insulin" in the following, which has been disclosed in European Patent Nos. (EP-B) 0,132,769  
30 and 0,132,770 (Published 07 January 1988), and of human insulin, but it also shows a certain insulin activity itself.

A



The invention therefore also relates to the compound of the formula I for use as a pharmaceutical, in particular for the treatment of diabetes mellitus, and furthermore pharmaceuticals containing the compound of the formula I, and pharmaceuticals composed of a pharmacologically acceptable excipient and the compound of the formula I.

The invention furthermore relates to the use of the compound of the formula I for the preparation of the mono-Arg insulin of the formula II



in which A(1-21) and B(1-30) have the meanings mentioned previously and the -S-S-bridges are arranged as in insulin, and of human insulin by enzymatic cleavage. The immediate conversion of the compound of the formula I into insulin in a "one-pot reaction" is particularly advantageous.

The invention furthermore relates to a process for the preparation of the compound of the formula I which comprises expressing a gene structure encoding for this compound in a host cell, preferably in a bacterium such as E. coli or in a yeast, in particular Saccharomyces cerevisiae, and, if the gene structure encodes for a fusion protein, liberating the compound of the formula I from this fusion protein. The invention relates in addition to DNA sequences which encode for the compound of the formula I, gene structures or plasmids which contain this DNA, and host cells, in particular bacteria such as E. coli or yeast cells, particularly yeasts of the strain Saccharomyces cerevisiae which contain such gene structures or plasmids. The invention furthermore

relates to fusion proteins which contain a compound of the formula I, preferably fusion proteins in which the compound of the formula I is bonded via the bridging member

5                   - Met - Ile - Glu - Gly - Arg -

to the "ballast component" of the fusion protein.

Further preferred embodiments of the invention are explained in more detail in the following.

10           The figures are used to explain the Examples, Fig. 1 (and its continuation in Fig. 1a and 1b) showing the construction of the E. coli expression vectors PIK10 and pSW3 and Fig. 2 (and its continuation in Fig. 2a and 2b) showing that of the yeast expression vector pafB102 or pafB104. These vectors encode for mini-proinsulin.

15           It has been found that the mini-proinsulin has the correct folding so that mono-Arg insulin is formed almost quantitatively after cleavage with trypsin. A surprisingly simple process for the preparation of mono-Arg insulin thus results. Human insulin can be prepared from  
20           this in a manner known per se. Mono-Arg insulin is furthermore used as an active compound in pharmaceuticals (EP-B 0,132,769, Published 07 January 1988).

25           The expression vector pK50 was described in EP-A 0,229,998 (Published 29 July 1987). Mini-proinsulin can be prepared in a bacterium such as E. coli in the form of a fusion protein corresponding to this construction.

30           The poorly soluble fusion protein can be concentrated by washing with neutral buffer solutions. The mini-proinsulin is liberated by cyanogen halide cleavage (E. Gross and B. Wittkop, J. Am. Chem. Soc. 82 (1961) 1510-1517). This still does not exist in the

7

biologically active form, but consists of a non-uniform mixture having various inter- and intramolecular disulfide bridges, possibly also with other protein fragments. The S-sulfonate form of the molecule is prepared as a chemically uniform, relatively stable derivative (P.G. Katsoyannis et al., *Biochemistry* 6 (1967) 2635-2641). This derivative can be purified very easily by ion exchange chromatography and is an approved starting material for the folding into the native spatial structure with the formation of the correct disulfide bridges (Y.C. Du et al., *Sci. Sin.* 15 (1965) 229-236; H.P. Gattner et al., *Hoppe-Seylers Z. physiol. Chem.* 362 (1981) 1943-1049; B.H. Frank et al. in: "Peptides: Synthesis-Structure-Function", D.H. Rich and E. Gross, Publishers, (1981) 1043-1049). The success of this folding is safeguarded by HPLC analysis of the fragments resulting after cleavage with *S. aureus* protease V8 (U. Grau, *Diabetes* 34 (1985) 1174-1180).

The liberation of mono-Arg insulin or insulin by the action of trypsin or carboxypeptidase B or by enzymes having the same action (W. Kemmler et al., *J. Biol. Chem.* 246 (1971) 2780-2795) proceeds in a decidedly uncomplicated manner, since it proves particularly advantageous for this purpose that the number of possible cleavage sites is reduced compared to normal proinsulin. Because of this, the cleavage is considerably more simple to control (with respect to the formation of side products as in the preparation of Des-B30 insulin or Desocta-B23-B30 insulin). Both mono-Arg insulin and also insulin can be isolated in a known manner in highly pure form by ion exchange chromatography. The formation of the insulin and the mono-Arg derivative, the course of the purification and the quality of the final product are checked using customary RP-HPLC methods (G. Seipke et al., *Angew. Chem.* 98 (1986) 530-548).

Surprisingly, hardly any insulin Des-B30 is formed in the cleavage of mini-proinsulin in contrast to natural



proinsulin. Since the latter can only be separated from insulin in a very difficult manner, the "two-pot reaction" is preferred in the production of insulin from natural proinsulin, i.e. the principal products of the tryptic cleavage, insulin-Arg<sup>B31</sup>-Arg<sup>B32</sup> and mono-Arg insulin are first separated from insulin Des-B30 via ion exchangers in a known manner and then cleaved to give human insulin by means of carboxypeptidase B (EP-A 0,195,691, Published 24 September 1986). In comparison, mini-proinsulin can be converted to human insulin in an ideal manner in a "one-pot reaction" simultaneously using trypsin and carboxypeptidase B or by means of enzymes having the same action.

The expression of the compound of the formula I in yeast with subsequent secretion is particularly advantageous, since the correctly folded proinsulin derivative can be isolated directly. Yeasts are used as host systems, for example *B. Pichia pastoris*, *Hansenula polymorphis*, *Schizosaccharomyces pombe* or, preferably *Saccharomyces cerevisiae*.

Vectors for expression in yeasts are known in large numbers. The preparation of the insulin derivative according to the invention is described in the following with the aid of the yeast  $\alpha$ -factor system which, however, is only to be taken as an example, since other expression systems can also be employed in a manner known per se.

The structure of the yeast pheromone gene MF $\alpha$  is known from the publication Kurjan and Herskovitz, Cell 30 (1982) 933-943, where the possibility of the expression of other genes and the secretion of the gene products are also discussed. Regarding this, reference can also be made to Brake et al., Proc. Natl. Acad. Sci. USA 81 (1984), 4642-4646.

AM

Alternatively, a yeast "Killertoxin" system can be used, or secretion via the acidic phosphatase or invertase system can be utilized.

5 As yeast vectors, so-called "shuttle" vectors are advantageously used which have a bacterial plasmid and a yeast plasmid replication origin and also a gene or genes for selection in both host systems. In addition, such vectors contain the promoter sequences necessary for the expression of foreign genes and, if appropriate, a  
10 terminator sequence to improve the yield so that the heterologous gene - expediently fused to secretory signals - is arranged between promoter and terminator. Such vectors are described, for example, in US-A 4,766,073.

15 The genetic code is, as is known, "degenerate", i.e. a single nucleotide sequence encodes only for two amino acids, while the residual 18 encodable amino acids are allocated two to six triplets. For the synthesis of the gene for mini-proinsulin, there is thus a large variety  
20 of codon combinations to be chosen. It has now been found that the DNA sequence I encoding for mini-proinsulin (which is reproduced in the Appendix in the form of the two gene fragments IK I (Table 1) and IK II (Table 2)) is particularly advantageous, since it is optimized  
25 to codon use of both yeast and E. coli.

A "protruding" DNA sequence corresponding to the restriction endonuclease KpnI is situated at the 5' end of the encoding strand of the DNA sequence I. In comparison, the single-stranded sequence corresponding to the restriction enzyme HindIII is protruding at the 3' end of the  
30 encoding strand. These two different recognition sequences ensure the insertion of the DNA sequence I into plasmids in the desired orientation. Two translation/-termination codons (stop codons) follow triplet No. 65  
35 for asparagine in the encoding sequence. An internal unique cleavage site for the restriction enzyme Pst I



(codon 41/42) makes possible the sub-cloning of two gene fragments which can be incorporated in well investigated plasmids such as pUC18 or derivatives of these plasmids.

5 Additionally, a number of further unique recognition sequences for restriction enzymes can be incorporated within the structure gene, which on the one hand provide access to partial sequences of proinsulin and on the other hand permit mutations to be carried out:

|    | Restriction enzyme | Cut. after nucleotide no.<br>(encoding strand) |
|----|--------------------|--|
| 10 | AccI               | 201  |
|    | DraIII             | 46   |
|    | FnuDII             | 107  |
|    | HgaI               | 105  |
| 15 | HindIII            | 213  |
|    | HinfI              | 17   |
|    | HpaI               | 22   |
|    | HphI               | 76   |
|    | MaeI               | 155  |
| 20 | MaeIII             | 191  |
|    | MboII              | 89   |
|    | MluI               | 106  |
|    | NcoI               | 207  |
|    | NlaIII             | 208  |
| 25 | PvuII              | 175  |
|    | SalI               | 201  |
|    | SpeI               | 154  |
|    | StyI               | 207  |
|    | TaqI               | 202  |

30 The DNA sequence I was modified from the natural sequence at essential points. In this way, the insertion of the numerous unique cleavage sites for restriction enzymes was possible.

35 The DNA sequence I can be constructed from a total of 6 oligonucleotides having a chain length of 47 to 96

nucleotide units. For this purpose, the procedure is as described in the following.

5 The gene fragment IK I (Table 1) can be constructed from 4 oligonucleotides having a chain length of 47 to 74 units by first synthesizing these chemically and then linking them enzymatically via "sticky ends" of 3 nucleotides. The sticky ends correspond to those of the restriction enzyme DraIII, which is advantageous for later modifications.

10 The gene fragment IK II (Table 2) can be obtained from two chemically synthesized oligonucleotides having a length of 88 and 96 nucleotide units.

#### Example 1

15 a) Chemical synthesis of a single-stranded oligonucleotide

20 The synthesis of the DNA building blocks is explained using oligonucleotide No. 4 (Table 1) as an example. For the solid phase synthesis, the nucleoside at the 3' end, i.e. adenine (nucleotide No. 125) in the present case, is used bonded covalently to a support via the 3'-hydroxyl function. The support material is CPG ("controlled pore glass") functionalized with long-chain aminoalkyl radicals.

25 In the following synthetic steps, the base component is employed as  $\beta$ -cyanoethyl N,N'-dialkyl-5'-O-dimethoxytritylnucleoside-3'-phosphoramidite, where the adenine is present as the N<sup>6</sup>-benzoyl compound, the cytosine as the N<sup>4</sup>-benzoyl compound, the guanine as the N<sup>2</sup>-isobutyl compound and the thymine without a protective group.

30 25 mg of the polymeric support, which contains 0.2  $\mu$ mol of 5'-O-dimethoxytrityl-N<sup>4</sup>-benzoyl-2'-desoxyadenosine

bonded, are successively treated with the following agents:

- A) acetonitrile
- B) 3% trichloroacetic acid in dichloromethane
- 5 C) acetonitrile
- D) 5  $\mu$ mol of the appropriate nucleoside-3'-O-phosphite and 25  $\mu$ mol of tetrazole in 0.15 ml of anhydrous acetonitrile
- E) acetonitrile
- 10 F) 20% acetic anhydride in tetrahydrofuran containing 40% lutidine and 10% dimethylaminopyridine
- G) acetonitrile
- H) 3% iodine in lutidine/water/tetrahydrofuran in a volume ratio of 5:4:1

15 In this connection, "phosphite" is taken to mean  $\beta$ -cyanoethyl 2'-desoxyribose-3'-monophosphite, the third valency being satisfied by a diisopropylamino radical. The yields of the individual synthesis steps can in each case be determined spectrophotometrically by the detritylation reaction B) by measuring the absorption of the dimethoxytrityl cation at the wavelength of 496 nm.

20

After synthesis has been concluded, the cleavage of the dimethoxytrityl group is carried out as described in A) to C). The oligonucleotide is cleaved from the support by treatment with ammonia and the  $\beta$ -cyanoethyl groups are eliminated at the same time. The amino protective groups of the bases are cleaved quantitatively by treatment of the oligomers with concentrated ammonia at 50°C for 16 hours. The crude product thus obtained is purified by polyacrylamide gel electrophoresis.

25

30

The oligonucleotides 1 -3 (Table 1), 5 and 6 (Table 2) are prepared in an analogous manner.

b) Enzymatic linkage of the single-stranded oligonucleotides

For enzymatic phosphorylation of the oligonucleotides at the 5' terminus, each 1  $\mu$ mol of the oligonucleotides 1 and 4 is treated for 30 minutes at 37°C with four units of T4 polynucleotide kinase in 20  $\mu$ l of 50 mM tris-HCl buffer (pH 7.6), 10 mM of magnesium chloride and 10 mM of dithiothreitol (DTT). The enzyme is inactivated by heating to 95°C for 5 minutes. The oligonucleotides 2 and 3, which form the "protruding" single-stranded sequences, are not phosphorylated. This prevents the formation of larger gene fragments in the subsequent ligation.

The oligonucleotides 1 to 4 are ligated as follows: each 1  $\mu$ mol of the oligonucleotides 1 and 2 or 3 and 4 are hybridized in pairs by dissolving these in each case in 20  $\mu$ l of 50 mM tris-HCl buffer (pH 7.6), 10 mM of magnesium chloride and 10 mM of DTT, heating this solution to 95°C for 5 minutes and cooling to room temperature within 2 hours. For this purpose, the oligonucleotides 1 and 4 are employed in the form of their 5'-phosphates. For further linking of the bihelical DNA fragments formed, the solutions of these are combined, warmed to 60°C for 15 minutes and cooled to room temperature. 2  $\mu$ l of 0.1 M DDT, 16  $\mu$ l of 2.5 mM adenosine triphosphate (pH 7) and 1  $\mu$ l of T4 DNA ligase (400 units) are then added and the mixture is incubated at 22°C for 16 hours.

The purification of the gene fragments thus obtained (Tables 1 and 2) is carried out by gel electrophoresis on a 10% strength polyacrylamide gel (without addition of urea, 40 x 20 x 0.1 cm),  $\phi$ X174 DNA (BRL) cleaved using HinfI, or pBR322, cut using HaeIII, being used as a labeling substance.

### a) Cloning of the synthesized DNA fragments

15 Accordingly, the DNA (5) according to Table 2 is ligated into pUC19 which has been opened using PstI and HindIII (4). The plasmid pIK2 (6) is obtained.

20 The DNA sequences (2) and (5) according to Table 1 and 2 are reisolated from the plasmids pIK1 (3) and pIK2 (6) and ligated with pUC19, which has been opened using KpnI and HindIII (7). The plasmid pIK3 (8) is thus obtained which encodes for a modified human insulin sequence.

25      The plasmid pIK3 (8) is opened using MluI and SpeI and  
the large fragment (9) is isolated. This is ligated with  
the DNA sequence (10)

[illegible]



which supplements the last codon of the B chain (B30) by one arginine codon and replaces the excised codon for the first 7 amino acids of the A chain and supplements the codon for the amino acids 8 and 9 of this chain.


- 5 The plasmid pIK4 (11) is thus obtained, which encodes for the human mini-proinsulin according to the invention.

c) Expression vectors for mini-proinsulin

pIK I:

- 10 The plasmid pK50 (12) known from EP-A 0,229,998 (Example 3 therein; Figure 3 (33)) is cleaved using EcoRI and HindIII. Both fragments (13) and (14) are isolated. The small fragment (14) containing the IL-2 partial sequence is subsequently cleaved with MluI and the IL-2 partial sequence (15) is isolated.

- 15 The plasmid pIK4 (11) is cleaved using EcoRI and HpaI and the large fragment (16) is isolated. This is now ligated with the IL-2 partial sequence (15) and the synthetic DNA (17)



- 25 the plasmid pIK8 (18) being obtained. This encodes for a fusion protein in which a bridging member Met-Ile-Glu-Gly-Arg and then the amino acid sequence of the mini-proinsulin follow the first 38 amino acids of the IL-2.

- 30 The EcoRI-HindIII fragment which encodes for the fusion protein mentioned is excised from the plasmid pIK8 (18). This fragment is ligated with the large fragment (13) which was obtained in the cleavage of pK50. The expres-

sion vector pIK10 (20) which encodes for the previously characterized fusion protein is thus obtained.

pSW3:

5 If the NdeI-BstEII segment which includes the "bom site" is removed from the vector pIK10 (20), a vector is obtained which is present in the cell in a relatively high copy number and - on account of the missing "bom site" - can no longer be mobilized by conjugative plasmids.

10 For this purpose, the vector pIK10 (20) is cleaved using BstEII and NdeI, which is precipitated using ethanol, transferred in DNA polymerase buffer and subjected to a Klenow polymerase reaction. The truncated DNA fragments thus formed are separated by gel electrophoresis and the  
15 larger fragment (21) is isolated. The vector pSW3 (22) is obtained by ligation. After transformation of competent *E. coli*-Mc1061 cells and amplification, the plasmid pSW3 (22) is isolated and characterized.

Example 3: Expression in the strain *E. coli* W3110

20 An overnight culture of *E. coli* cells which contain the plasmid pIK10 (20) or pSW3 (22) is diluted in a ratio of about 1:100 using LB medium (J.H. Miller, Experiments in Molecular Genetics, Cold Spring Harbor Laboratory, 1972) which contains 50  $\mu$ g/ml of ampicillin and the growth is  
25 followed by means of OD measurement. At OD = 0.5, the culture is adjusted to 1 mM IPTG and the bacteria are centrifuged off after 150 to 180 minutes. The bacteria are boiled for 5 minutes in a buffer mixture (7 M urea, 0.1% SDS, 0.1 M sodium phosphate, pH 7.0) and samples are  
30 applied to an SDS gel electrophoresis plate. After analysis by gel electrophoresis, an additional band is observed in the region from about 10 Kd, which corresponds to the fusion protein expected. This band reacts with antibodies directed against insulin in the "Western  
35 Blot" experiment. If the cells are disintegrated under

pressure and the debris is centrifuged off, the fusion protein is found in the sediment in addition to other insoluble cell constituents.

5 The induction conditions indicated apply to shaken cultures; with larger fermentations the choice of other media and conditions, for example in order to obtain changed O.D. values, is expedient.

Example 4:

a) Preparation of mono-Arg insulin

10 40 g of the fusion protein concentrated by centrifugation and washing with phosphate buffer (pH 7) or water (dry substance content about 25%) are dissolved in 75 ml of 98-100% strength phosphoric acid and 5 g of BrCN are added. After reacting for 6 hours at room temperature,  
15 2 l of water are added to the mixture and it is freeze-dried.

The fragment mixture (10 g) is dissolved in 1 l of buffer solution (8 M urea, 0.2 M tris-HCl (pH 8.5)), warmed to 30°C and 10 g of sodium sulfite and 2.5 g of sodium tetrathionate are added. After 90 minutes at 30°C, 3 l  
20 of cold water are added and the pH is adjusted to 7.0. The resulting precipitate is centrifuged off. The hexa-S-sulfonate of the mini-proinsulin is precipitated from the supernatant by adjusting the pH to 3.5. The mixture  
25 is centrifuged after incubating for 15 hours at +4°C. The precipitate is washed with 200 ml of water and freeze-dried. 4.8 g of a substance mixture in which a mini-proinsulin content of 900 mg is determined by RP-HPLC are obtained. The concentration of the S sulfonate  
30 is carried out in two steps:

1. Anion exchange chromatography through a 5 x 60 cm column containing Fractogel TSK DEAE 650 M in 3 M urea; 0.05 M tris-HCl (pH 8.3). The elution is

performed using a gradient of 0.05-0.5 M NaCl (each 6 l). After analysis of the eluate by isoelectric focusing, the product is precipitated from the combined fractions by diluting to 1 M urea and adjusting the pH to 3.5.

2. Removal of high and low molecular weight impurities by gel filtration through <sup>\*</sup>Sephacryl S200 in 3 M urea; 0.05 M tris-HCl; 0.05 M NaCl (pH 8.3). Analysis of the fractions and isolation of the product are carried out as in the preceding step. The precipitate is washed with 20 ml of water and freeze-dried. 1.10 g of product cocentrated to 69% purity are obtained.

For folding and disulfide bridge formation, the S sulfonate is dissolved in 50 ml of 8 M urea; 0.02 M tris-HCl at pH 8.6. After addition of a few drops of octanol, purified nitrogen is passed into the mixture for 15 minutes. Complete reduction is carried out in the course of 1 hour at room temperature by addition of 1.1 ml (16 mMol) of 2-mercaptoethanol. The solution is applied to a <sup>\*</sup>Sephadex G25 column (5 x 60 cm) and eluted using 0.05 M glycine/NaOH (pH 10.6). The protein fraction in 300 ml of the glycine buffer is kept for 2 days at 4°C after checking and, if necessary, correction of the pH value (10.6). The solution is then adjusted to a pH of 6.8 and the solution is incubated at room temperature for 4 hours with 1 mg (3.5 U) of trypsin (Merck, treated with L-1-p-tosylamino-2-phenylethylchloromethyl ketone (TPCK). The pH is then adjusted to 3.5, 1 mg of soya bean trypsin inhibitor (Sigma) and 3 ml 10% ZnCl<sub>2</sub> are added and the solution is readjusted again to pH 6.8. The resulting precipitate is separated by centrifugation. It contains predominantly mono-Arg insulin which is purified by ion exchange chromatography on S-Sepharose<sup>\*</sup> (2.5 x 40 cm) in a buffer composed of 50 mM lactic acid and 30% isopropanol (pH 3.5). Elution is carried out by means of a gradient of 0.05-0.50 M of NaCl (each 1 l). The eluate is analyzed by HPLC; the mono-Arg insulin is precipitated

from the product-containing fractions after 1:1 dilution with H<sub>2</sub>O by adding 10 ml of 10% ZnCl<sub>2</sub> per 1 l and adjusting the pH to 6.8. The precipitate separated by centrifugation is crystallized at pH 6 from a buffer composed of 1 g/l of phenol, 10.5 g/l of citric acid and 200 mg/l of ZnCl<sub>2</sub>. 390 mg of mono-Arg insulin in over 90% purity are obtained after freeze-drying the crystals washed with some water.

Example 5:

10 Preparation of insulin

200 mg of mono-Arg insulin (see Example 4) are dissolved in 100 ml of 0.05 M tris-HCl (pH 8.5). 1 U (about 4 µg) of carboxypeptidase B is then added and the solution is stirred slowly at room temperature. After 3 hours, the human insulin is crystallized by acidifying to pH 3.5 and adding 1 ml of 10% ZnCl<sub>2</sub> at pH 5.5. 200 mg of crystalline insulin having a purity of more than 85% are obtained. This material is subjected to purification by ion exchange chromatography on a column containing Fractogel TSK DEAE 650 M (2.5 x 40 cm) in 0.1% Lutensol ON 100 (BASF AG; oxethylate of a linear saturated fatty alcohol of essentially 12 carbon atoms); 0.05 M tris-HCl (pH 8.3), the elution being carried out using a gradient of 0-0.4 M NaCl (each 1 l). The insulin is crystallized at pH 5.5 from the product-containing fractions identified by means of HPLC after addition of 10 ml of 10% ZnCl<sub>2</sub> and 1 ml of 10% citric acid. After slowly stirring overnight, the mixture is centrifuged and the sediment obtained is recrystallized at pH 5.5 from 20 ml of a buffer composed of 5 g/l of citric acid, 125 ml/l of acetone and 200 mg/l of ZnCl<sub>2</sub>. 160 mg of insulin having a purity of more than 95% are obtained.



## Example 6:

Preparation of insulin from mono-Arg insulin by combined use of trypsin and carboxypeptidase B

5 mg of mono-Arg insulin are dissolved in 20 ml of 0.1 M  
5 of tris-HCl (pH 8.0) and the solution is warmed to 30°C.  
At the same time, 2.5  $\mu$ l of trypsin solution (1 U/ml) and  
150  $\mu$ l of carboxypeptidase B solution (1 U/ml) are added.  
After 3 hours, the solution is adjusted to pH 3.5 and 2.5  
10  $\mu$ l of trypsin inhibitor solution (1 U/ml) and 200  $\mu$ l of  
10% strength ZnCl<sub>2</sub> solution are added. The human insulin  
is precipitated by adjusting to pH 6.8, centrifuged off  
and crystallized as in Example 5. The crystallized  
insulin has a purity > 95%.

## Example 7: Construction of a yeast expression vector

15 The DNA sequence (23) (Table 3) is first synthesized by  
the phosphite method. This DNA sequence (23) encodes for  
the amino acids 49 to 80 of the MF $\alpha$  precursor protein and  
corresponds essentially to the natural DNA sequence.

20 The DNA sequence (23) is first used as a probe for the  
isolation of the gene for the  $\alpha$  factor and is labeled  
with <sup>32</sup>P for this purpose. With the aid of this probe,  
the gene is isolated from a genomic  $\lambda$ gt11 yeast gene bank  
(as are meanwhile commercially available and obtainable,  
for example, at Clontech Laboratories Inc., 4055 Fabian  
25 Way, Palo Alto, CA94303). To this end,  $\lambda$ gt11 phages  
which carry the  $\alpha$  factor gene are identified in a plaque  
hybridization experiment. Phages from plaques identified  
as positive are isolated, replicated and the DNA ob-  
tained. This is cleaved using EcoRI and analyzed on a  
30 0.8% strength agarose gel. The membrane is hybridized  
against the <sup>32</sup>P-labeled DNA sequence (23) by a "Southern  
transfer" experiment. Phage DNA which contains a frag-  
ment of about 1.75 kb (24) which is hybridized against  
the DNA sequence (23) is again cleaved with the enzyme

and the corresponding fragment (24) is isolated. The vector pUC 19 is opened using EcoRI (25) and reacted with the 1.75 kb fragment (24) using T4 ligase. The cloning vector (26) is obtained.

- 5 The strain E. coli 79/02 is transformed using the ligation mixture. White colonies are isolated, the plasmid DNA is obtained from these and plasmids (26) which contain the 1.75 kb EcoRI fragment, are identified.

10 The natural DNA sequence of the precursor protein for MF $\alpha$  contains a PstI cleavage site in the region of amino acids 8 to 10 and a TaqI cleavage site in the region of amino acids 48/49. From the isolated plasmid DNA (26), the fragment (27) which encodes for the amino acids 9 to 48 of the MF $\alpha$  precursor sequence is isolated by reaction  
15 with PstI and TaqI. The vector pUC18 is opened using PstI and KpnI and reacted with the PstI-TaqI fragment (27) and with the synthetic DNA sequence (23) with the aid of T4 ligase. E. coli 79/02 is transformed using the ligation mixture. The transformation mixture is plated  
20 out on to IPTG-Xgal-Ap-plates. White colonies are isolated and the plasmid DNA of this clone is characterized by restriction analysis. The cloning vector (29) which encodes for the amino acids 8 to 80 of the MF $\alpha$  precursor sequence is thus obtained.

- 25 The encoding sequence (30) mentioned is excised from the cloning vector (29) by reaction with PstI and KpnI and incorporated in the ligation described in the following. For this purpose, the cloning vector (26) is reacted with EcoRI and partially with PstI and the fragment (31)  
30 including the encoding sequence for the first 8 amino acids of the MF $\alpha$  precursor sequence is isolated. Furthermore, the vector pUC19 is opened using EcoRI and KpnI (32) and ligated with the two fragments (30) and (31) described, the cloning vector (33) being formed. This  
35 encodes for the total precursor sequence of MF $\alpha$  up to amino acid 80.

The cloning vector (33) is opened using KpnI and HindIII and the large fragment (34) is isolated. This is ligated using the KpnI-HindIII fragment (35) from the plasmid (11) which encodes for the mini-proinsulin. The plasmid  
5 pIK20 (36), the structure of which is confirmed by restriction analysis, is thus obtained.

The plasmid Yep13 (Broach et al., Gene 8 (1979) 121) is opened using BamHI and the protruding ends are filled in with Klenow polymerase (38). The DNA is precipitated  
10 using ethanol and treated with alkaline bovine phosphatase.

The fragment encoding for the insulin derivative and the precursor sequence of MF<sub>a</sub> is excised from the cloning vector (36) using HindIII and EcoRI and the protruding  
15 ends are filled in as described (37).

The two truncated DNA sequences (37) and (38) are ligated with one another, the plasmids pafB102 (39) and pafB104 (40) being formed. These two plasmids differ only in the orientation of the inserted fragment.

As described in EP-A 0,171,024 (Published 12 February 1986), a terminator can be inserted behind the inserted sequence (Figures 4 to 6 of EP-A 0,171,024). For this  
20 purpose, the NcoI and/or the BamHI cleavage sites are suitable.

After amplification of the plasmid DNA in E. coli MM294, the plasmid pafB102 (39) is transformed in the leucine-requiring yeast strain Y79 ( $\alpha$ ,trp1,leu2-1) (Cantrell et al., Proc. Acad. Natl. Sci. USA 82 (1985) 6250) and DM6-6 ( $\alpha/\alpha$  leu2-3,112::ura3<sup>+</sup>/leu2::lys2<sup>+</sup>, trp1<sup>-</sup>/trp1<sup>-</sup>, his3-11, 15/his3-11, 15, ura3<sup>-</sup>/ura3<sup>-</sup>, lys2<sup>-</sup>/lys2<sup>-</sup>, arg4-17/arg4<sup>+</sup>,  
25 adel/adel<sup>+</sup>) (Maya Hanna, Dept. Mol. Biol. Massachusetts General Hospital, Boston, USA) by the lithium method of Ito, H. et al., J. Bacteriol., 153 (1983) 163. Colonies  
30 which can grow on selective medium without addition of

leucine, are isolated and combined. Yeast minimum medium is inoculated with the individual colonies and incubated at 28°C for 24 hours. The cells are centrifuged off and the supernatant is tested for insulin activity in an RIA test. The plasmid DNA is reisolated from yeast clones whose supernatant shows insulin activity, and characterized by restriction analysis. The transformed yeast strains are employed for the following expression.

Example 8: Expression in yeast

10 ml of yeast complete medium is inoculated with cells which have been removed from a fresh overnight culture of a strain of selective medium obtained according to Example 7, in such a way that an optical density  $OD_{600} = 0.1$  is achieved. The culture is shaken at 28°C for 8 hours, after which 90 ml of fresh medium are added. The culture is then shaken for a further 20 hours. The cells are centrifuged off and the insulin concentration is determined in the supernatant. The conditions are modified for a larger fermentation, for example fresh medium can be added continuously.

Example 9: Purification of mono-Arg insulin from yeast supernatant

The fermentation supernatant is added through an adsorption column containing a porous adsorber resin composed of a copolymer of styrene and divinylbenzene (Diaion HP 20). The column was previously equilibrated with a 20-50 mM acetate buffer (pH 5). After washing with tris buffer (pH 8), an isopropanol gradient (0-50%) is applied using a 10-fold column volume. Insulin-containing fractions are adjusted to pH 6, MATREX CELLUFINE AM (Amicon) is added, and the mixture is stirred and filtered off with suction and washed with 50 mM acetate buffer (pH 6). The wash fraction and the main fraction are combined, adjusted to pH 3.5 using lactic acid and



added through an S-SEPHAROSE column which has been equilibrated using 50 mM lactic acid (pH 5)/30% isopropanol.

5 The elution is carried out by means of a 0-0.6 M NaCl gradient. Mini-proinsulin elutes in the range 0.25-0.3 M.

10 The proinsulin-containing fractions are concentrated to 1/4 of the volume and added through a column containing Biogel\* P10 (Bio-Rad), equilibrated in 6% acetic acid (pH 2). The insulin-containing eluate is lyophilised and purified through a preparative "reversed phase" HPLC step (RP18 material, 0.1% TFA, acetonitrile gradient 20-40%). After subsequent freeze-drying, the lyophilisate is dissolved in tris buffer (pH 6.8) and incubated for 3 to 15 5 hours at room temperature with 4 units of trypsin per gramme of mono-Arg proinsulin. The course of the reaction is checked by "reversed-phase" analysis. It shows that mono-Arg insulin is formed nearly quantitatively. At the end of the reaction, the pH is adjusted to 3.5 and 20 the reaction is completed by addition of an equivalent amount of trypsin inhibitor. The zinc chloride concentration is then adjusted to 0.21 g/l and the pH to 6.8. A flocculent precipitate is obtained which is dissolved in lactic acid buffer. The components are 25 separated from one another by means of S-SEPHAROSE chromatography. Fractions which contain mono-Arg insulin are combined and mixed with water in the ratio 1:1. 10 ml of 10% ZnCl<sub>2</sub> per 1 l are then added to the solution. Mono-Arg insulin then precipitates at pH 6.8 and is 30 recrystallized in a known (for insulin) manner.

#### Example 10: Preparation of human insulin

The mono-Arg insulin prepared according to Example 9 is used as a starting substance for the carboxypeptidase B cleavage. To this end, the insulin derivative is 35 dissolved in tris buffer (pH 8.5) and 5 units of



\* Denotes Trade-mark



carboxypeptidase per gramme of mono-Arg insulin are added. The reaction is carried out over the course of 3 hours with slow stirring at room temperature. The product is then precipitated with  $\text{ZnCl}_2$ , as described in  
5 Example 9. Human insulin is then purified in a known manner (DE-B 2,629,568).

Table 1: Gene fragment IK I (2)

B<sup>1</sup>  
Phe

| 10  | 20 | 30   | 40 |
|---|----|------|----|
| <-----2----->   |    |      |    |
| CT TTG GAC AAG AGA TTC GTT AAC CAA CAC TTG TGT GGT TCT CAC      |    |      |    |
| CAT GGA AAC CTG TTC TCT AAG CAA TTG GTT GTG AAC ACA CCA AGA GTG |    |      |    |
| <-----1----->   |    |      |    |
| (KpnI)  |    | HpaI |    |

| 50  | 60 | 70 | 80 | 90 |
|---|----|----|----|----|
| <-----4----->   |    |    |    |    |
| TTG GTG GAA GCG TTG TAC TTG GTT TGT GGT GAG CGT GGT TTC TTC |    |    |    |    |
| AAC CAC CTT CGC AAC ATG AAC CAA ACA CCA CTC GCA CCA AAG AAG |    |    |    |    |
| <-----3----->   |    |    |    |    |

B<sup>30</sup>  
Thr Arg Lys Gly Ser Leu

| 100  | 110 | 120    |
|--|-----|--------|
| <----->                                      |     |        |
| TAC ACT CCA AAG ACG CGT AAG GGT TCT CTG CA   |     |        |
| ATG TGA GGT TTC <u>TGC GCA</u> TTC CCA AGA G |     |        |
| <----->                                      |     |        |
| MluI   |     | (PstI) |

Table 2: Gene fragment IK II (5)

A<sup>1</sup>  
Gln Lys Arg Gly

| 130   | 140 | 150  | 160 |
|---|-----|------|-----|
| <-----6   |     |      |     |
| G AAG CGT GGT ATC GTT GAA CAA TGT TGT ACT AGT ATC TGT TCT             |     |      |     |
| AC GTC TTC GCA CCA TAG CAA CTT GTT ACA ACA <u>TGA TCA</u> TAG ACA AGA |     |      |     |
| <-----5   |     |      |     |
| (PstI)  |     | SpeI |     |

A<sup>21</sup>  
Asn

| 170   | 180 | 190 | 200 | 210       |
|---|-----|-----|-----|-----------|
| ----->  |     |     |     |           |
| TTG TAC CAG CTG GAA AAC TAC TGT AAC TGA TAG TCG ACC CAT GGA       |     |     |     |           |
| AAC ATG GTC GAC CTT TTG ATG ACA TTG ACT ATC AGC TGG GTA CCT TCG A |     |     |     |           |
| ----->  |     |     |     |           |
|   |     |     |     | (HindIII) |

Table 3: DNA sequence (23)

|        |                                     |    |
|--------|-------------------------------------|----|
|        | 50                                  | 55 |
| 5'     | C GAT GTT GCT GTT TTG CCA TTC TCC   |    |
| 3'     | TA CAA CGA CAA AAC GGT AAG AGG      |    |
| (TaqI) |                                     |    |
|        | 60                                  | 65 |
|        | AAC AGT ACT AAT AAC GGT TTA TTG TTC |    |
|        | TTG TCA TGA TTA TTG CCA AAT AAC AAG |    |
|        | 70                                  |    |
|        | ATT AAT ACT ACT ATT GCT AGC ATT GCT |    |
|        | TAA TTA TGA TGA TAA CGA TCG TAA CGA |    |
|        | 75                                  | 80 |
|        | GCT AAA GAA GAA GGG GTA C           | 3' |
|        | CGA TTT CTT CTT CCC                 | 5' |
|        | (KpnI)                              |    |

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A compound of the formula I



in which B(1-30) and A(1-21) denote the B and A chain of human insulin.

2. A use of the compound of the formula I as defined in claim 1 for use as a pharmaceutical.

3. The use of the compound of claim 2 for the treatment of diabetes mellitus.

4. A pharmaceutical composed of a pharmacologically acceptable excipient and the compound of the formula I as defined in claim 1.

5. The use of the compound of the formula I as defined in claim 1 for the preparation of insulin or for the preparation of the compound of the formula II



in which A(1-21) and B(1-30) have the meaning mentioned in claim 1 and the -S-S- bridges are arranged as in insulin.

6. The use of claim 5 wherein the preparation of the compound of the formula II is done in a one-pot reaction.



- 27 -

7. A process for the preparation of the compound of the formula I as defined in claim 1 which comprises expressing a gene structure encoding for this compound in a host cell.
8. The process as claimed in claim 7 wherein the host cell is a bacterium or a yeast.
9. A DNA, encoding for the compound of the formula I as defined in claim 1.
10. A plasmid containing the DNA as claimed in claim 9.
11. A host cell comprising a plasmid as claimed in claim 10.
12. The host cell of claim 11 wherein the host cell is a bacterium or a yeast.
13. A fusion protein containing the compound of the formula I as defined in claim 1.
14. A process for the preparation of the compound of the formula II as defined in claim 5 which comprises expressing a gene structure encoding for a fusion protein containing a compound as defined in claim 1 in a host cell and liberating the compound of the formula II from the fusion protein obtained.
15. A fusion protein containing the compound of the formula I as defined in claim 1 and the bridging member

- Met - Ile - Glu - Gly - Arg -.


13









16. A process for the preparation of insulin which comprises expressing a gene structure encoding for a compound of the formula I as defined in claim 1 in a host cell and liberating insulin from the compound obtained.

17. A process for the preparation of insulin which comprises expressing a gene structure encoding for a fusion protein as defined in claim 13 in a host cell and liberating insulin from the fusion protein obtained.


18. A process for the preparation of insulin which comprises expressing a gene structure encoding for a fusion protein as defined in claim 15 in a host cell and liberating insulin from the fusion protein obtained.

19. The process as claimed in claim 14, 16, 17 or 18, wherein the host cell is a bacterium or a yeast.





By: Roger Bereski & Pam









FIG. 1b



By: Roger Bereski &amp; Pam





















FIG. 2





By: Bogdan Bereskin & Pan

FIG. 2a



By Roger Beneski & Pan

FIG. 2b



By Roger Bereski & Pam